Dr. Michaela L. Tsai, MD

Dr. Tsai practices at Swedish Medical Center -First Hill in Seattle, Washington.

Dr. Tsai's NPI, 1801872502, was assigned on December 15, 2005. Dr. Tsai graduated from Harvard Medical School in 1995. Dr. Tsai holds Washington license MD61182267.

Dr. Tsai's primary practice is Swedish Medical Center -First Hill, at 747 Broadway, Seattle, WA 98122 in King County. The practice phone is (206) 386-6000.

Dr. Tsai's primary practice is Swedish Medical Center -First Hill in Seattle, Washington. Dr. Tsai is also affiliated with Swedish First Hill Campus. The medical group on file is Swedish Health Services. Dmand AI also links Dr. Tsai to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsai practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tsai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tsai is licensed in Washington.

CMS data shows 580 Medicare services from Dr. Tsai across 5 procedure codes in 2024, for 156 Medicare patients. Medicare paid $31,497 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 156 Medicare patients who saw Dr. Tsai in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have cancer, and 67% have high cholesterol. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tsai's median patient age at 71, with 98% women.

In 2024, Dr. Tsai wrote 788 Medicare Part D claims for 194 patients. 90% of them were for generic drugs. CMS names the drug for 664 of them, across 12 drugs with 11 or more claims each, at $612,045 in total drug cost. In 2023, CMS named 561 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Tsai for performance year 2024, reported as part of a group. Dr. Tsai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsai as offering telehealth.

Dmand AI links 27 papers to Dr. Tsai, published from 2011 to 2024. 2016 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Biomarkers, Tumor. Dr. Tsai has published most often in Clin Breast Cancer. Dr. Tsai's most frequent co-authors are Barbara Susnik, MD, Sami G. Diab, MD and Anne Hudson Blaes, MD.

Dmand AI links Dr. Tsai to 11 clinical trials, 2 of them phase 1/2 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Brain Neoplasms. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Tsai that name 2 trials.

CMS Open Payments shows 14 general payments to Dr. Tsai from 6 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 92% of the total. Genentech, Inc. paid the most, $3,576. It also lists 4 research payments totaling $2,289 from 2018 to 2023, naming 2 clinical trials.

Dr. Tsai graduated from Harvard Medical School in 1995.